Your Running Days Are Numbered!

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

October 25th 2023

Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Your daily dose of the clinical news you may have missed.

August 30th 2023

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Regulatory Submission / image credit obese man asleep / ©motortion/stock.adobe.com

Tezepelumab for COPD Moves into Phase 3 Planning

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

Related Content

April 18th 2024

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

October 25th 2023

Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Your daily dose of the clinical news you may have missed.

August 30th 2023

Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Tezepelumab for COPD Moves into Phase 3 Planning

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.